G1 Therapeutics, Inc. is making waves in the world of commercial-stage biopharmaceutical companies, focusing on the discovery, development, and commercialization of small molecule therapeutics for cancer patients. The company's flagship product, COSELA, has shown promising results in decreasing chemotherapy-induced myelosuppression in adult patients, making it a potential game-changer in the field. But that's not all - G1 Therapeutics is also developing trilaciclib, a CDK 4/6 inhibitor that can protect bone marrow and reduce hematologic adverse events. The company believes that trilaciclib has the potential to not only improve emerging treatments through myeloprotection but, when used in combination with an antibody-drug conjugate, also improve patients' overall anti-tumor immune responses. Additionally, G1 Therapeutics is working on lerociclib, an oral CDK 4/6 inhibitor that shows promise for multiple oncology indications. They're also developing rintodestrant, an oral selective estrogen receptor degrader, for HER2-negative breast cancer. G1 Therapeutics has secured license agreements with EQRx, Inc. and Genor Biopharma Co. Inc. for the development and commercialization of lerociclib, as well as Nanjing Simcere Dongyuan Pharmaceutical Co., LTD. for the development and commercialization of trilaciclib. They've also partnered with ARC Therapeutics for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses. Founded in 2008 and headquartered in Research Triangle Park, North Carolina, G1 Therapeutics, Inc. is making a name for itself among biopharmaceutical companies, with potentially life-saving therapies for cancer patients on the horizon.
G1 Therapeutics's ticker is GTHX
The company's shares trade on the NASDAQ stock exchange
They are based in Research Triangle Park, North Carolina
There are 51-200 employees working at G1 Therapeutics
It is g1therapeutics.com
G1 Therapeutics is in the Healthcare sector
G1 Therapeutics is in the Biotechnology industry
The following five companies are G1 Therapeutics's industry peers: